{
    "clinical_study": {
        "@rank": "67018", 
        "arm_group": [
            {
                "arm_group_label": "Bepotastine besilate Concentration 1", 
                "arm_group_type": "Experimental", 
                "description": "Bepotastine besilate nasal spray, BID for 14 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo nasal spray BID for 14 days"
            }, 
            {
                "arm_group_label": "Bepotastine besilate Concentration 2", 
                "arm_group_type": "Experimental", 
                "description": "Bepotastine besilate nasal spray, BID for 14 days."
            }, 
            {
                "arm_group_label": "Bepotastine besilate Concentration 3", 
                "arm_group_type": "Experimental", 
                "description": "Bepotastine besilate nasal spray, BID for 14 days."
            }, 
            {
                "arm_group_label": "Bepotastine besilate Concentration 4", 
                "arm_group_type": "Experimental", 
                "description": "Bepotastine besilate nasal spray, BID for 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine dose ranging characteristics of bepotastine besilate nasal spray\n      compared to placebo nasal spray in 600 male or female subjects 12 years of age and older\n      with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic\n      sensitivity to Mountain Cedar pollen for at least 2 years prior to the study."
        }, 
        "brief_title": "Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject is a male or female 12 years of age or older.\n\n          -  Have a documented history of SAR resulting from exposure to Mountain Cedar pollen for\n             a minimum of 2 years immediately preceding Screening Visit 1.\n\n          -  Have demonstrated sensitivity to Mountain Cedar pollen through a standard skin prick\n             test.\n\n          -  Have a minimum rTNSS of at least 6 units for the AM assessment on the day of Visit 2\n             and Visit 3.\n\n          -  Have a minimum average rTNSS score of at least 6 units for 3 of the worst 4 days\n             prior to Visit 3 plus the AM assessment on the day of Visit 3.\n\n          -  Have a minimum stuffy nose score of at least 2 units on the day of Visit 3.\n\n          -  Have a minimum average stuffy nose score of at least 2 units for 3 of the worst 4\n             days prior to Visit 3 plus the AM assessment on the day of Visit 3.\n\n          -  Have at least one score \u2265 2 units at Visit 3 of any of the RQLQ(S) questions #4-#6\n             regarding sleep.\n\n        Exclusion Criteria:\n\n          -  Have a nasal condition which, in the opinion of the Investigator, interferes with\n             successful nasal drug administration or absorption (in either nostril) within the\n             last 60 days prior to Screening Visit 2.\n\n          -  Have asthma requiring medication other than intermittent use of an inhaled\n             short-acting \u03b2-agonist.\n\n          -  Is participating or have participated in any investigational drug or device study\n             within 30 days preceding Visit 2.\n\n          -  Have had nasal or sinus surgery within 12 weeks of Visit 2.\n\n          -  Have a known sensitivity to bepotastine besilate or any excipient component of the\n             IP.\n\n          -  For female subjects 12 years of age or older (other than those who have been\n             menopausal for at least 24 months or those who are surgically sterile), are pregnant,\n             planning to become pregnant, or nursing/lactating, or refuses to abide by the\n             contraception stipulations in the inclusion criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "615", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753739", 
            "org_study_id": "823"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bepotastine besilate Concentration 1", 
                    "Bepotastine besilate Concentration 2", 
                    "Bepotastine besilate Concentration 3", 
                    "Bepotastine besilate Concentration 4"
                ], 
                "description": "Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days", 
                "intervention_name": "Bepotastine besilate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92618-2301"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Dose-Ranging Study to Evaluate the Safety and Efficacy of Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects With a Demonstrated History of Mountain Cedar Pollen Allergic Sensitivity", 
        "other_outcome": {
            "description": "Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ[S])", 
            "measure": "Total and Individual Mean domain scores", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Jon Williams, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Improvement from baseline in averaged AM and PM values for reflective total nasal symptom score (rTNSS). Nasal symptoms rated on a 4 point (0-3 units) scale where 0=none and 3=severe.", 
            "measure": "Nasal Symptoms Score", 
            "safety_issue": "No", 
            "time_frame": "14 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement from baseline in averaged AM and PM values for reflective total nasal symptom score (rTNSS) by day. Nasal symptoms rated on a 4 point (0-3 units) scale where 0=none and 3=severe.", 
                "measure": "Nasal Symptom Score by day", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "description": "Improvement from baseline for additional total and individual nasal and ocular symptom scores other than rTNSS.", 
                "measure": "Nasal and Ocular Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "description": "Proportion of subjects that achieve a 50% reduction in rTNSS from baseline", 
                "measure": "50% reduction in Nasal Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}